BioCentury
ARTICLE | Company News

Alliance Pharma, Cambridge Laboratories deal

February 15, 2010 8:00 AM UTC

Specialty pharmaceutical company Alliance will acquire Cambridge Labs for up to £14.3 million ($22.3 million) in cash plus potential milestones of up to £2.1 million ($3.3 million). Alliance gains 18 marketed prescription drugs in the U.K. and Ireland, including ImmuCyst, a Connaught strain of Bacillus of Calmette and Guerin (BCG) to treat and prevent non-muscle invasive bladder cancer; and procarbazine, a methylhydrazine derivative partnered with Sigma-Tau S.p.A. (Rome, Italy) to treat Hodgkin's disease. Cambridge Labs had 2009 sales of £10.6 million ($16.6 million). ...